Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

Secondary Use of Patients' Electronic Records (SUPER): An Approach for Meeting Specific Data Needs of Clinical and Translational Researchers.

Sholle ET, Kabariti J, Johnson SB, Leonard JP, Pathak J, Varughese VI, Cole CL, Campion TR Jr.

AMIA Annu Symp Proc. 2018 Apr 16;2017:1581-1588. eCollection 2017.

2.

Establishing the Feasibility of a Tablet-Based Consent Process with Older Adults: A Mixed-Methods Study.

Jayasinghe N, Isabel Moallem B, Kakoullis M, Ojie MJ, Sar-Graycar L, Wyka K, Reid MC, Leonard JP.

Gerontologist. 2018 May 11. doi: 10.1093/geront/gny045. [Epub ahead of print]

PMID:
29757375
3.

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C.

J Geriatr Oncol. 2018 Apr 17. pii: S1879-4068(18)30131-0. doi: 10.1016/j.jgo.2018.03.018. [Epub ahead of print]

PMID:
29673807
4.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

PMID:
29641966
5.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.

Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW.

Haematologica. 2018 Apr;103(4):e151-e153. doi: 10.3324/haematol.2017.175059. Epub 2018 Feb 22. No abstract available.

6.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD.

Ann Oncol. 2018 Jan 29. doi: 10.1093/annonc/mdx812. [Epub ahead of print] No abstract available.

PMID:
29390097
7.

Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee.

Rutherford SC, Leonard JP.

Br J Haematol. 2018 Jan 29. doi: 10.1111/bjh.15113. [Epub ahead of print] No abstract available.

PMID:
29377067
8.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.

J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.

PMID:
29356608
9.

A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.

Ghione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi MC, Dogliotti I, Nicolosi M, Boccadoro M, Leonard JP, Vitolo U, Martin P.

Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15057. [Epub ahead of print] No abstract available.

PMID:
29265185
10.

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP.

Br J Haematol. 2017 Dec;179(5):739-747. doi: 10.1111/bjh.14951. Epub 2017 Oct 29.

PMID:
29082519
11.

Lymphoma "benchmark" or "bench-smudge"?

Rutherford SC, Leonard JP.

Blood. 2017 Oct 19;130(16):1778-1779. doi: 10.1182/blood-2017-08-800730. No abstract available.

PMID:
29051150
12.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD.

Ann Oncol. 2017 Nov 1;28(11):2806-2812. doi: 10.1093/annonc/mdx496.

PMID:
28945884
13.

The potential for chemotherapy-free strategies in mantle cell lymphoma.

Martin P, Ruan J, Leonard JP.

Blood. 2017 Oct 26;130(17):1881-1888. doi: 10.1182/blood-2017-05-737510. Epub 2017 Sep 12. Review.

PMID:
28899853
14.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
15.

Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.

Rutherford SC, Li V, Ghione P, Chen Z, Martin P, Leonard JP.

Br J Haematol. 2017 Oct;179(2):242-245. doi: 10.1111/bjh.14839. Epub 2017 Jul 5.

PMID:
28677889
16.

Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.

Leonard JP, Martin P, Roboz GJ.

J Clin Oncol. 2017 Aug 10;35(23):2708-2715. doi: 10.1200/JCO.2017.72.6745. Epub 2017 Jun 27. Review.

PMID:
28654364
17.

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.

Leuk Lymphoma. 2018 Jan;59(1):256-258. doi: 10.1080/10428194.2017.1323270. Epub 2017 Jun 2. No abstract available.

PMID:
28573908
18.

The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval.

Rutherford SC, Leonard JP.

Oncology (Williston Park). 2017 May 15;31(5):412, 414. No abstract available.

19.

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP.

Br J Haematol. 2017 Jul;178(2):250-256. doi: 10.1111/bjh.14667. Epub 2017 Apr 17.

PMID:
28419413
20.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

21.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP.

Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.

22.

BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SN, Oswald E, Graham CW, Jiang Y, Hatzi K, Agirre X, Perkey E, Li Z, Tam W, Bhatt K, Leonard JP, Zweidler-McKay PA, Maillard I, Elemento O, Ci W, Aifantis I, Melnick A.

Cancer Discov. 2017 May;7(5):506-521. doi: 10.1158/2159-8290.CD-16-1189. Epub 2017 Feb 23.

23.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR.

J Natl Cancer Inst. 2016 Dec 31;109(1). pii: djw263. doi: 10.1093/jnci/djw263. Print 2017 Jan. Review.

PMID:
28040733
24.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL.

J Natl Cancer Inst. 2016 Dec 31;109(4). pii: djw249. doi: 10.1093/jnci/djw249. Print 2017 Apr. Review.

PMID:
28040700
25.

Recommendations for Clinical Trial Development in Follicular Lymphoma.

Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM.

J Natl Cancer Inst. 2016 Dec 31;109(3). pii: djw255. doi: 10.1093/jnci/djw255. Print 2017 Mar. Review.

PMID:
28040699
26.

T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.

Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, Kahl BS, Little RF, Pinter-Brown L, Advani R, Horwitz S.

J Natl Cancer Inst. 2016 Dec 31;109(2). doi: 10.1093/jnci/djw248. Print 2017 Feb. Review.

PMID:
28040682
27.

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.

Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW.

Br J Haematol. 2017 Mar;176(5):759-769. doi: 10.1111/bjh.14480. Epub 2016 Dec 19.

28.

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM.

J Natl Cancer Inst. 2016 Dec 16;108(12). pii: djw257. doi: 10.1093/jnci/djw257. Print 2016 Dec. Review.

PMID:
27986884
29.

General Biomarker Recommendations for Lymphoma.

Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M, Baizer L, Fu K, Hsi E, Chan JW, McShane L, Leonard JP, Kahl BS, Little RF, Friedberg JW, Kostakoglu L.

J Natl Cancer Inst. 2016 Dec 16;108(12). pii: djw250. Print 2016 Dec.

PMID:
27986882
30.

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS.

Lancet Haematol. 2017 Jan;4(1):e24-e34. doi: 10.1016/S2352-3026(16)30166-1. Epub 2016 Dec 1.

31.

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP.

Blood Adv. 2016 Nov 30;1(2):122-131. doi: 10.1182/bloodadvances.2016000976. eCollection 2016 Dec 13.

32.

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD.

Blood. 2016 Nov 24;128(21):2510-2516. Epub 2016 Oct 3.

33.

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, Abbott J, Tam W, Du W, Leonard JP, Elemento O, Cerchietti L, Cierpicki T, Xue F, MacKerell AD Jr, Melnick AM.

J Clin Invest. 2016 Sep 1;126(9):3351-62. doi: 10.1172/JCI85795. Epub 2016 Aug 2.

34.

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.

Marullo R, Rutherford SC, Leonard JP, Cerchietti L.

Cell Cycle. 2016 Sep;15(17):2241-7. doi: 10.1080/15384101.2016.1207839. Epub 2016 Jul 15.

35.

Behavioral and physiological characterization of PKC-dependent phosphorylation in the Grin2a∆PKC mouse.

Balu D, Larson JR, Schmidt JV, Wirtshafter D, Yevtodiyenko A, Leonard JP.

Brain Res. 2016 Sep 1;1646:315-326. doi: 10.1016/j.brainres.2016.06.022. Epub 2016 Jun 15.

36.

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.

Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM.

Br J Haematol. 2016 Sep;174(5):686-91. doi: 10.1111/bjh.14100. Epub 2016 Apr 13.

37.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW.

J Clin Oncol. 2016 Jun 10;34(17):2020-7. doi: 10.1200/JCO.2015.63.1119. Epub 2016 Apr 11.

38.

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.

Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, Allaire A, Cromwell MA, Wang B, Grabowski GA, Leonard JP, Cheng SH.

Mol Ther. 2016 Jun;24(6):1019-1029. doi: 10.1038/mt.2016.53. Epub 2016 Mar 7.

39.

Lenalidomide plus Rituximab for Mantle-Cell Lymphoma.

Ruan J, Leonard JP.

N Engl J Med. 2016 Feb 25;374(8):793. doi: 10.1056/NEJMc1515465. No abstract available.

PMID:
26933862
40.

CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.

Leonard JP, Gregory SA, Smith H, Horner TJ, Williams VC, Giampietro P, Lin TS.

Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):191-6. doi: 10.1016/j.clml.2015.12.011. Epub 2016 Jan 4.

PMID:
26832194
41.

Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma.

Tang T, Chen Z, Praditsuktavorn P, Khoo LP, Ruan J, Lim ST, Tan D, Phipps C, Lee YS, Goh YT, Hwang W, Tao M, Quek R, Farid M, Furman RR, Leonard JP, Martin P.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):117-21. doi: 10.1016/j.clml.2015.12.006. Epub 2015 Dec 21.

PMID:
26796979
42.

Postibrutinib outcomes in patients with mantle cell lymphoma.

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA.

Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13.

43.

Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia.

Pizzi M, Covey S, Mathew S, Liu YC, Ruan J, Leonard JP, Chadburn A.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):e47-50. doi: 10.1016/j.clml.2015.11.019. Epub 2015 Nov 26. No abstract available.

PMID:
26708981
44.

Foraging decisions in wild versus domestic Mus musculus: What does life in the lab select for?

Troxell-Smith SM, Tutka MJ, Albergo JM, Balu D, Brown JS, Leonard JP.

Behav Processes. 2016 Jan;122:43-50. doi: 10.1016/j.beproc.2015.10.020. Epub 2015 Nov 6.

PMID:
26548716
45.

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard JP.

N Engl J Med. 2015 Nov 5;373(19):1835-44. doi: 10.1056/NEJMoa1505237.

46.

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A.

J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.

47.

Idelalisib-associated Colitis: Histologic Findings in 14 Patients.

Weidner AS, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, Jessurun J, Yantiss RK.

Am J Surg Pathol. 2015 Dec;39(12):1661-7. doi: 10.1097/PAS.0000000000000522.

PMID:
26448188
48.

Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy.

Jacobs SE, Lamson DM, Soave R, Guzman BH, Shore TB, Ritchie EK, Zappetti D, Satlin MJ, Leonard JP, van Besien K, Schuetz AN, Jenkins SG, George KS, Walsh TJ.

J Clin Virol. 2015 Oct;71:51-8. doi: 10.1016/j.jcv.2015.07.309. Epub 2015 Jul 29.

49.

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD.

J Clin Oncol. 2015 Nov 1;33(31):3635-40. doi: 10.1200/JCO.2014.59.9258. Epub 2015 Aug 24.

50.

Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.

Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, Desnick RJ, Scheule RK, Leonard JP, Cheng SH, Marshall J.

Mol Med. 2015 Apr 30;21:389-99. doi: 10.2119/molmed.2015.00088.

Supplemental Content

Loading ...
Support Center